Ipamorelin: A Selective Growth Hormone Secretagogue — Research Overview
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that has attracted significant research interest due to its selective pharmacological profile. With the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 and a molecular weight of approximately 711.85 Da, Ipamorelin interacts with the growth hormone secretagogue receptor (GHSR, also known as the ghrelin receptor) to stimulate growth hormone release from the anterior pituitary gland. Its distinguishing characteristic in preclinical research is selectivity — Ipamorelin promotes GH release without the significant concurrent effects on cortisol, prolactin, and ACTH observed with earlier-generation secretagogues.
For a broader overview of peptide science, see our comprehensive guide: What Are Peptides?
Origin and Development
Ipamorelin was developed in the late 1990s as part of the iterative refinement of growth hormone secretagogue peptides. The GHS class originated with the discovery that synthetic peptides could stimulate GH release through a receptor distinct from the GHRH receptor — a finding that preceded the identification of ghrelin (the endogenous GHSR ligand) by several years.
Early GHS compounds — GHRP-6, GHRP-2, Hexarelin — were effective GH releasers but produced unwanted side effects including cortisol elevation, prolactin stimulation, and significant appetite increase (via the same ghrelin receptor pathway). Ipamorelin was designed to retain GH-releasing activity while minimizing these off-target effects, and published studies confirmed this selective profile in animal models.
The peptide's sequence contains several non-standard amino acids: Aib (alpha-aminoisobutyric acid), D-2-Nal (D-2-naphthylalanine), and D-Phe (D-phenylalanine). These modifications contribute to both receptor selectivity and metabolic stability — D-amino acid substitutions in particular resist enzymatic degradation more effectively than their L-amino acid counterparts.
Mechanism of Action
Ghrelin Receptor (GHSR) Signaling
Ipamorelin acts as an agonist at the growth hormone secretagogue receptor (GHSR), a G-protein coupled receptor (GPCR) expressed primarily in the hypothalamus and anterior pituitary. When Ipamorelin binds GHSR, it activates a signaling cascade involving phospholipase C, inositol triphosphate (IP3), and intracellular calcium release, which ultimately triggers GH vesicle exocytosis from somatotroph cells in the anterior pituitary.
A 2009 study published in the European Journal of Endocrinology examined Ipamorelin's effects in rat models and confirmed its selective GH-releasing activity. The investigators observed dose-dependent GH release without significant changes in cortisol, ACTH, prolactin, FSH, LH, or TSH levels — a selectivity profile that distinguished Ipamorelin from GHRP-6 tested in parallel (PMID: 19022896).
GH Pulsatility
An important characteristic of Ipamorelin-stimulated GH release is that it appears to preserve normal pulsatile GH secretion patterns in animal models, rather than producing a sustained, non-physiological elevation. This pulsatility is considered significant because the biological effects of GH are mediated in part by the pattern of secretion — pulsatile release activates different gene expression profiles than continuous exposure.
Selectivity Mechanism
The basis for Ipamorelin's selectivity relative to earlier GHS compounds is not fully characterized but is believed to relate to its specific binding mode at the GHSR. GHRP-6, for example, also activates the GHSR but appears to engage additional receptor conformations or signaling pathways that lead to cortisol and prolactin co-stimulation. Ipamorelin's modified amino acid sequence may produce a more constrained receptor interaction that preferentially activates the GH release pathway.
Published Research — Key Study Summaries
Selectivity Study (2009)
A study in the European Journal of Endocrinology provided the most widely cited characterization of Ipamorelin's selective GH release in rat models. The study compared Ipamorelin to GHRP-6 at equivalent doses and observed that while both compounds produced comparable GH release, Ipamorelin did not significantly elevate cortisol, prolactin, or ACTH levels. This selective profile was observed across multiple dose levels (PMID: 19022896).
GH Axis Modulation
Published studies have examined Ipamorelin's effects on the broader GH axis, including its interactions with somatostatin (the endogenous GH inhibitor) and IGF-1 (the primary downstream mediator of GH's peripheral effects). Research in rodent models has observed that Ipamorelin-stimulated GH release leads to downstream IGF-1 elevation, confirming activation of the physiological GH-IGF-1 signaling axis.
Gastrointestinal Motility Research
An unexpected area of Ipamorelin research involves gastrointestinal motility. The ghrelin receptor is expressed in the GI tract as well as the pituitary, and published studies have examined Ipamorelin's effects on gastric emptying and intestinal transit in animal models. A study in the Journal of Surgical Research observed pro-kinetic effects of Ipamorelin in rat models of post-operative ileus (PMID: 18468640), suggesting activity at peripheral GHSR sites in addition to pituitary GH release.
Bone Metabolism
Research in rodent models has examined the effects of GH secretagogues, including Ipamorelin, on bone metabolism parameters. GH and its downstream mediator IGF-1 are established regulators of bone formation and resorption. Published studies have examined whether Ipamorelin-mediated GH release translates to measurable effects on bone mineral density and osteoblast activity in animal models.
Combination with CJC-1295
The combination of Ipamorelin (GHSR agonist) with CJC-1295 (GHRH receptor agonist) has been studied based on the rationale that activating both GH-releasing pathways simultaneously may produce synergistic amplification of GH pulsatility. The two compounds target different receptors — GHSR and GHRH-R — representing distinct nodes of the hypothalamic-pituitary GH axis. Published research has examined the GH release kinetics of this combination in laboratory settings.
Comparison with Other GH Secretagogues
Ipamorelin belongs to a class that includes several other GHS compounds, each with distinct selectivity profiles:
GHRP-6 — Potent GH releaser but also stimulates cortisol, prolactin, and appetite (via ghrelin-like signaling). Less selective than Ipamorelin.
GHRP-2 — More potent than GHRP-6 for GH release, but still produces cortisol and prolactin elevation. Intermediate selectivity.
Hexarelin — The most potent GHS for raw GH output but with the least selectivity. Significant cortisol and prolactin co-stimulation.
Ipamorelin — Comparable GH release potency to GHRP-6 but with minimal cortisol, prolactin, and ACTH effects. Most selective GHS in published research.
CJC-1295 — Acts through GHRH receptor, not GHSR. Different mechanism entirely. Often studied in combination with Ipamorelin.
Purity and Quality Considerations
Ipamorelin's pentapeptide structure with non-standard amino acids requires careful synthesis quality control. The D-amino acid residues and the Aib modification must be correctly incorporated — incorrect stereochemistry at any position would alter receptor binding and compromise research results.
Research-grade Ipamorelin should meet the following minimum specifications:
- Purity: ≥98% as measured by HPLC
- Identity: Confirmed by mass spectrometry (expected MW ~711.85 Da)
- Appearance: White to off-white lyophilized powder
- Documentation: Certificate of Analysis with HPLC chromatogram and MS data
View CALM Peptides' quality and testing standards →
Available for Research
CALM Peptides offers research-grade Ipamorelin at ≥98% purity with Certificates of Analysis available upon request. Also available: CJC-1295 for researchers studying dual-pathway GH axis modulation.
For research use only. Not for human consumption.
Frequently Asked Questions
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that interacts with the ghrelin receptor to stimulate growth hormone release. It has been studied for its selective GH-releasing properties — promoting GH release without significant concurrent effects on cortisol, prolactin, or ACTH levels.
How is Ipamorelin different from other growth hormone secretagogues?
Ipamorelin's distinguishing characteristic is its selectivity. Earlier GHS compounds like GHRP-6 and GHRP-2 stimulate GH release but also increase cortisol, prolactin, and appetite signaling. Published studies have observed that Ipamorelin promotes GH release without significant effects on these other hormonal axes.
What is the difference between Ipamorelin and CJC-1295?
They act through different receptors. Ipamorelin signals through the ghrelin receptor, while CJC-1295 acts through the GHRH receptor. They target different nodes of the GH axis, which is why they are often studied in combination.
What is Ipamorelin's amino acid sequence?
Ipamorelin's sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. It is a pentapeptide with a molecular weight of approximately 711.85 Da containing non-standard amino acids that contribute to receptor selectivity and metabolic stability.
How should Ipamorelin be stored for research use?
Lyophilized Ipamorelin should be stored at -20°C or colder in a sealed container protected from moisture and light. Reconstituted Ipamorelin should be refrigerated at 2–8°C and used within the supplier's recommended timeframe.
The information presented in this article is for educational and informational purposes only and is not intended as medical advice. All products referenced are sold as research chemicals for laboratory use only. They are not intended for human consumption and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.